Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | UTHR |
---|---|---|
09:32 ET | 12941 | 359.37 |
09:34 ET | 14183 | 357.1 |
09:36 ET | 200 | 357.925 |
09:38 ET | 300 | 359.37 |
09:41 ET | 100 | 359.105 |
09:45 ET | 957 | 359.02 |
09:48 ET | 100 | 359.515 |
09:56 ET | 100 | 359.815 |
09:59 ET | 200 | 359.955 |
10:01 ET | 100 | 360.21 |
10:06 ET | 1333 | 360.37 |
10:10 ET | 200 | 360.37 |
10:12 ET | 230 | 360.37 |
10:14 ET | 200 | 360.37 |
10:17 ET | 1213 | 359.955 |
10:19 ET | 224 | 359.605 |
10:21 ET | 600 | 360 |
10:24 ET | 100 | 359.39 |
10:28 ET | 2701 | 359.54 |
10:30 ET | 300 | 359.645 |
10:37 ET | 600 | 360.27 |
10:39 ET | 307 | 360.285 |
10:48 ET | 500 | 360.1049 |
10:50 ET | 1100 | 359.7 |
10:51 ET | 100 | 359.84 |
11:02 ET | 810 | 359.98 |
11:04 ET | 500 | 359.845 |
11:09 ET | 705 | 359.8 |
11:11 ET | 100 | 359.56 |
11:13 ET | 500 | 359.595 |
11:15 ET | 100 | 359.6 |
11:18 ET | 200 | 359.985 |
11:22 ET | 301 | 359.79 |
11:24 ET | 630 | 359.805 |
11:27 ET | 851 | 359.35 |
11:31 ET | 100 | 358.96 |
11:42 ET | 100 | 358.345 |
11:51 ET | 202 | 358.27 |
11:56 ET | 100 | 358.275 |
12:03 ET | 100 | 357.69 |
12:05 ET | 100 | 357.96 |
12:09 ET | 100 | 357.69 |
12:12 ET | 100 | 358.32 |
12:18 ET | 200 | 357.93 |
12:30 ET | 220 | 358.695 |
12:32 ET | 173 | 358.265 |
12:41 ET | 200 | 358.175 |
12:45 ET | 100 | 358.19 |
12:50 ET | 200 | 358.035 |
12:52 ET | 250 | 358.035 |
12:56 ET | 400 | 357.38 |
12:57 ET | 100 | 357.73 |
12:59 ET | 100 | 357.38 |
01:01 ET | 100 | 357.41 |
01:03 ET | 431 | 357.14 |
01:06 ET | 805 | 357 |
01:08 ET | 200 | 356.695 |
01:12 ET | 200 | 356.5976 |
01:14 ET | 271 | 356.5469 |
01:17 ET | 100 | 356.48 |
01:24 ET | 200 | 356.305 |
01:26 ET | 288 | 356.1041 |
01:28 ET | 300 | 356.305 |
01:30 ET | 100 | 356.305 |
01:33 ET | 100 | 356.11 |
01:37 ET | 100 | 356.16 |
01:42 ET | 800 | 356.305 |
01:44 ET | 2446 | 356.565 |
01:46 ET | 111 | 356.3936 |
01:51 ET | 100 | 356.485 |
01:53 ET | 1742 | 356.485 |
01:55 ET | 200 | 356.485 |
01:57 ET | 900 | 356.025 |
02:00 ET | 500 | 356.08 |
02:02 ET | 200 | 356.135 |
02:04 ET | 200 | 356.125 |
02:09 ET | 200 | 355.86 |
02:13 ET | 100 | 355.1 |
02:15 ET | 100 | 355.025 |
02:22 ET | 700 | 354.065 |
02:26 ET | 1179 | 353.845 |
02:27 ET | 600 | 354.12 |
02:29 ET | 100 | 354.94 |
02:31 ET | 500 | 355.19 |
02:33 ET | 100 | 355.19 |
02:36 ET | 100 | 355.54 |
02:38 ET | 472 | 355.95 |
02:40 ET | 100 | 356.075 |
02:44 ET | 200 | 356.38 |
02:45 ET | 2008 | 356.12 |
02:47 ET | 1500 | 356.405 |
02:51 ET | 200 | 356.41 |
02:54 ET | 788 | 356.1 |
02:56 ET | 100 | 356.095 |
03:02 ET | 924 | 355.805 |
03:03 ET | 1100 | 356.28 |
03:05 ET | 100 | 356.35 |
03:07 ET | 322 | 356.34 |
03:09 ET | 1720 | 356.32 |
03:14 ET | 2700 | 355.03 |
03:16 ET | 600 | 354.73 |
03:18 ET | 200 | 355.16 |
03:20 ET | 1300 | 355.665 |
03:21 ET | 600 | 355.995 |
03:25 ET | 1000 | 356.108 |
03:27 ET | 992 | 356.17 |
03:30 ET | 300 | 355.91 |
03:32 ET | 500 | 356.155 |
03:34 ET | 500 | 355.7 |
03:36 ET | 700 | 355.74 |
03:38 ET | 700 | 355.95 |
03:39 ET | 200 | 355.7 |
03:41 ET | 800 | 356.2 |
03:43 ET | 900 | 356.989 |
03:45 ET | 400 | 356.57 |
03:48 ET | 400 | 356.5 |
03:50 ET | 900 | 356.71 |
03:52 ET | 900 | 356.97 |
03:54 ET | 600 | 357.6 |
03:56 ET | 1627 | 357.97 |
03:57 ET | 3869 | 358.695 |
03:59 ET | 93941 | 358.14 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
United Therapeutics Corp | 15.1B | 16.5x | +8.22% |
Biomarin Pharmaceutical Inc | 16.2B | 53.0x | --- |
Exact Sciences Corp | 12.1B | -70.9x | --- |
Neurocrine Biosciences Inc | 12.3B | 34.8x | +62.04% |
Qiagen NV | 10.4B | 143.2x | +12.66% |
Medpace Holdings Inc | 10.9B | 31.4x | +35.10% |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.1B |
---|---|
Revenue (TTM) | $2.6B |
Shares Outstanding | 44.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $21.75 |
Book Value | $127.23 |
P/E Ratio | 16.5x |
Price/Sales (TTM) | 5.8 |
Price/Cash Flow (TTM) | 13.4x |
Operating Margin | 48.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.